Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy

Cancer Biology and Therapy

Volumn 16, Issue 12, 2015, Pages 1710-1719

  Marks, Eric I ^a   Tan, Carlyn ^b   Zhang, Jun ^b   Zhou, Lanlan ^b   Yang, Zhaohai ^a   Scicchitano, Angelique ^a   El Deiry, Wafik S ^a,b  

^a PENN STATE CANCER INSTITUTE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

5 FU; capecitabine; metastatic colorectal adenocarcinoma; regorafenib

Indexed keywords

B RAF KINASE; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; DABRAFENIB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB; PROTEIN BCL XL; PROTEIN MCL 1; REGORAFENIB; SORAFENIB; TRAMETINIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; TUMOR MARKER;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CASE REPORT; COLORECTAL CANCER CELL LINE; COLOSTOMY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIARRHEA; DRUG DOSE REDUCTION; DRUG POTENTIATION; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HYPERBILIRUBINEMIA; LUNG EMBOLISM; LYMPHADENOPATHY; MALE; METASTATIC COLORECTAL CANCER; MIDDLE AGED; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; BIOPSY; COLORECTAL NEOPLASMS; METASTASIS; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RETREATMENT; TREATMENT OUTCOME; TUMOR CELL LINE; X-RAY COMPUTED TOMOGRAPHY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BIOPSY; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PHENYLUREA COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; PYRIMIDINES; RETREATMENT; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84954553406     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2015.1113355     Document Type: Article

References (23)

1. R.L.Siegel, K.D.Miller, A.Jemal. Cancer statistics, 2015. CA Cancer J Clin 2015; 65(1):5–29; PMID:25559415; http://dx.doi.org/10.3322/caac.21254
2. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. 2013 (Available from: http://globocan.iarc.fr, accessed on 9/12/2015).
3. E.Van Cutsem, B.Nordlinger, R.Adam, C.H.Kohne, C.Pozzo, G.Poston, M.Ychou, P.Rougier, European Colorectal Metastases Treatment Group. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Euro J Cancer 2006; 42(14):2212–21; PMID:16904315; http://dx.doi.org/10.1016/j.ejca.2006.04.012
4. Benson AB, Venook A, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS, et al. Rectal Cancer Version 2.2015. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®), 2015
5. M.L.Rothenberg, A.M.Oza, R.H.Bigelow, J.D.Berlin, J.L.Marshall, R.K.Ramanathan, L.L.Hart, S.Gupta, C.A.Garay, B.G.Burger, Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21(11):2059–69; PMID:12775730; http://dx.doi.org/10.1200/JCO.2003.11.126
6. M.Gubanski, G.Naucler, A.Almerud, A.Lidestahl, P.A.Lind. Capecitabine as third line therapy in patients with advanced colorectal cancer. Acta Oncol 2005; 44(3):236–9; PMID:16076695; http://dx.doi.org/10.1080/02841860510029662
7. R.J.Mayer, E.Van Cutsem, A.Falcone, T.Yoshino, R.Garcia-Carbonero, N.Mizunuma, K.Yamazaki, Y.Shimada, J.Tabernero, Y.Komatsu, Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 2015; 372(20):1909–19; PMID:25970050; http://dx.doi.org/10.1056/NEJMoa14-14325
8. S.M.Wilhelm, J.Dumas, L.Adnane, M.Lynch, C.A.Carter, G.Schutz, K.H.Thierauch, D.Zopf. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2011; 129(1):245–55; PMID:21170960; http://dx.doi.org/10.1002/ijc.25864
9. D.Strumberg, M.E.Scheulen, B.Schultheis, H.Richly, A.Frost, M.Buchert, O.Christensen, M.Jeffers, R.Heinig, O.Boix, Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Br J Cancer 2012; 106(11):1722–7; PMID:22568966; http://dx.doi.org/10.1038/bjc.2012.153
10. K.Mross, A.Frost, S.Steinbild, S.Hedbom, M.Buchert, U.Fasol, C.Unger, J.Krätzschmar, R.Heinig, O.Boix, A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 2012; 18(9):2658–67; PMID:22421192; http://dx.doi.org/10.1158/1078-0432.CCR-11-1900
11. A.Grothey, E.Van Cutsem, A.Sobrero, S.Siena, A.Falcone, M.Ychou, Y.Humblet, O.Bouché, L.Mineur, C.Barone, Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381(9863):303–12; PMID:23177514; http://dx.doi.org/10.1016/S0140-6736(12)61900-X
12. Research Center for Drug Evaluation and Research. Approved Drugs – Regorafenib [Internet]. U.S. Food and Drug Administration Center for Drug Evaluation and Research, 2015. [updated 09/27/2012 ; cited 12/9/2015].(Available from:http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm321378.htm)
13. N.J.Carter. Regorafenib: a review of its use in previously treated patients with progressive metastatic colorectal cancer. Drugs Aging 2014; 31(1):67–78; PMID:24276917; http://dx.doi.org/10.1007/s40266-013-0140-6
14. E.P.M.Van Cutsem, S.Siena, Y.Humblet, A.Hendlisz, B.Neyns, J.L.Canon, J.L.Van Laethem, J.Maurel, G.Richardson, M.Wolf, Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25:1658–64.; PMID:17470858; http://dx.doi.org/10.1200/JCO.2006.08.1620
15. D.J.Jonker, C.J.O'Callaghan, C.S.Karapetis, J.R.Zalcberg, D.Tu, H.J.Au, S.R.Berry, M.Krahn, T.Price, R.J.Simes, Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357(20):2040–8; PMID:18003960; http://dx.doi.org/10.1056/NEJMoa071834
16. F.Foubert, T.Matysiak-Budnik, Y.Touchefeu. Options for metastatic colorectal cancer beyond the second line of treatment. Dig Liver Dis 2014; 46(2):105–12; PMID:23954144; http://dx.doi.org/10.1016/j.dld.2013.07.002
17. C.Y.Lu, Y.S.Yeh, C.W.Huang, C.J.Ma, F.J.Yu, J.Y.Wang. FOLFIRI and regorafenib combination therapy with dose escalation of irinotecan as fourth-line treatment for patients with metastatic colon cancer according to UGT1A1 genotyping. Onco Targets Ther 2014; 7:2143–6; PMID:25473295; http://dx.doi.org/10.2147
18. B.Schultheis, G.Folprecht, J.Kuhlmann, R.Ehrenberg, U.T.Hacker, C.H.Köhne, M.Kornacker, O.Boix, J.Lettieri, J.Krauss, Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study. Ann Oncol 2013; 24(6):1560–7; PMID:23493136; http://dx.doi.org/10.1093/annonc/mdt056
19. G.Argiles, M.P.Saunders, F.Rivera, A.Sobrero, A.Benson3rd, C.Guillen Ponce, S.Cascinu, E.Van Cutsem, I.R.Macpherson, D.Strumberg, Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial. Eur J Cancer 2015; 51(8):942–9; PMID:25818084; http://dx.doi.org/10.1016/j.ejca.2015.02.013
20. C.Tournigand, T.André, E.Achille, G.Lledo, M.Flesh, D.Mery-Mignard, E.Quinaux, C.Couteau, M.Buyse, G.Ganem, FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22(2):229–37; PMID:14657227; http://dx.doi.org/10.1200/JCO.2004.05.113
21. B.I.Carr, A.Cavallini, C.Lippolis, R.D'Alessandro, C.Messa, M.G.Refolo, E.Quinaux, C.Couteau, M.Buyse, G.Ganem, Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery. J Cell Physiol 2013; 228(2):292–7; PMID:22777740; http://dx.doi.org/10.1002/jcp.24148
22. D.Chen, L.Wei, J.Yu, L.Zhang. Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis. Clin Cancer Res 2014; 20(13):3472–84; PMID:24763611; http://dx.doi.org/10.1158/1078-0432.CCR-13-2944
23. J.P.Plastaras, S.H.Kim, Y.Y.Liu, D.T.Dicker, J.F.Dorsey, J.McDonough, G.Cerniglia, R.R.Rajendran, A.Gupta, A.K.Rustgi, Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res 2007; 67(19)9443–9454; PMID:17909054; http://dx.doi.org/10.1158/0008-5472.CAN-07-1473